Table 1.

Lisavanbulin Monotherapy in Orthotopic PDX Models. Fourteen Orthotopic PDXs were Orally Dosed with Vehicle or 30 mg/kg Lisavanbulin (LIS) Once Daily Until Moribund. Bold italics rows were selected for Follow-up Studies

Line	MGMT Promoter Status	N per Group	Median Survival (Days)		P Value	% Change
			Vehicle	LIS
GBM6	Unmethylated	10	48	60	<.01	25%
GBM8	Methylated	10a	47	64	<.01	36%
GBM10	Unmethylated	10	35	38	.04	9%
GBM12	Methylated	10 a	23	31	<.01	35%
GBM15	Methylated	10	71	87	.41	22%
GBM22TMZ	Methylated	10	27	26	.55	−4%
GBM26	Unmethylated	10	51	66	<.01	29%
GBM39	Methylated	10	31	57	<.01	84%
GBM59	Methylated	10	45	56	.02	24%
GBM84	Methylated	10	56	73	<.01	30%
GBM108	Unmethylated	10	40	43	.11	8%
GBM115	Unmethylated	10a	139	183	.07	32%
GBM122	Unmethylated	10a	80	84	.28	5%
GBM150	Unmethylated	10	52	69	<.01	33%

^aVehicle group contained n = 9.